Medtech firms prioritize process automation for clinical trial collaboration.
PorAinvest
miércoles, 13 de agosto de 2025, 6:49 am ET1 min de lectura
VEEV--
The report underscores the significant challenges faced by medtech companies, including on-time data entry and data quality, document and data exchange, and monitoring and compliance. However, only 14% of medtechs with revenue over $1 billion and 24% with revenue under $1 billion have site collaboration tools in place, indicating a gap in the industry's efforts to improve trial efficiency and expedite study timelines [1].
Manual processes and regulatory compliance are cited as major hurdles, increasing operational costs and causing delays. To mitigate these risks, 58% of medtechs plan to prioritize data collection and cleaning in the next year. Additionally, nearly three-quarters (72%) of medtech organizations are planning to invest in AI and ML infrastructure to standardize data and make it AI-ready [1].
The study also highlights the importance of technology in simplifying and standardizing clinical workflows, enabling more effective collaboration with research sites, and speeding up trials. This shift towards technological solutions is driven by the need to balance economic pressures and new regulations, ensuring data integrity, operational efficiency, and connected processes across stakeholders [1].
References:
[1] https://www.prnewswire.com/news-releases/research-shows-medtechs-prioritizing-site-collaboration-and-data-quality-302527421.html
Veeva Systems has announced the results of its 2025 Veeva MedTech Clinical Benchmark study, which shows that clinical teams in the medical technology sector prioritize reducing manual processes (68%), improving study quality (56%), and gaining better visibility and control (55%) to streamline workflows, work more efficiently with sites, and speed up trials. The study highlights the potential of technology to simplify and standardize clinical trial workflows, improve collaboration, and accelerate research.
Veeva Systems has released the findings of its 2025 Veeva MedTech Clinical Benchmark, highlighting key priorities for clinical teams in the medical technology sector. The study, which surveyed over 100 clinical professionals, reveals that reducing manual processes (68%), improving study quality (56%), and enhancing visibility and control (55%) are top priorities to streamline workflows, improve collaboration, and accelerate research [1].The report underscores the significant challenges faced by medtech companies, including on-time data entry and data quality, document and data exchange, and monitoring and compliance. However, only 14% of medtechs with revenue over $1 billion and 24% with revenue under $1 billion have site collaboration tools in place, indicating a gap in the industry's efforts to improve trial efficiency and expedite study timelines [1].
Manual processes and regulatory compliance are cited as major hurdles, increasing operational costs and causing delays. To mitigate these risks, 58% of medtechs plan to prioritize data collection and cleaning in the next year. Additionally, nearly three-quarters (72%) of medtech organizations are planning to invest in AI and ML infrastructure to standardize data and make it AI-ready [1].
The study also highlights the importance of technology in simplifying and standardizing clinical workflows, enabling more effective collaboration with research sites, and speeding up trials. This shift towards technological solutions is driven by the need to balance economic pressures and new regulations, ensuring data integrity, operational efficiency, and connected processes across stakeholders [1].
References:
[1] https://www.prnewswire.com/news-releases/research-shows-medtechs-prioritizing-site-collaboration-and-data-quality-302527421.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios